M&A in pharma
Explores the merits of mega-deal in contrast to a more measured portfolio growth strategy
Patient Groups and the Global Pharmaceutical Industry
| Publication Date | January 2000 |
| ISBN | 1859784267 |
| Pages | 0 |
| Tables | n/a |
| Figures | n/a |
Print £200 $375 |
Add to Basket |
PDF £200 $375 Single user |
Add to Basket |
Patient advocacy groups have emerged as a key customer for the industry as they potentially hold a great deal of power and influence. Such 'added value' approaches are becoming common-place and the advent of abundant and well run patient advocacy groups has placed such company-patient group alliances to the top of the strategy agenda
Patients have organised themselves into patient advocacy groups on a grand scale and these have emerged as a key customer for the industry as they potentially hold a great deal of power and influence. Such 'added value' approaches are becoming common-place and the advent of abundant and well run patient advocacy groups has placed such company-patient group alliances to the top of the strategy agenda.
Features include:
- Chapters which outline the motives and business drivers for both groups that are encouraging such relationships
- Practical case studies of some of the better, more successful partnerships that have occurred and practical next steps for the industry and patient groups alike
- A review of the regulatory, legal and ethical considerations holding sway in each major area
- A directory of hundreds of known groups by geography and therapy-type
Contents
Executive Summary
1: A history of patient groups
The rise and rise of consumer-power
The birth of the patient group
The role of information technologies
Patient groups ? a background
Patient groups ? by geography
Common types of patient group
Umbrella groups
Patient support groups
Active/lobby groups
Research groups
Patient groups by geographical area Australia
Aboriginal and Islander health: delivering community programmes
Belgium
Canada
France
Germany
Netherlands
Italy
The UK
Industry associations
Government initiatives
The US
NGOs by therapy area
Act Up! ? case study
Other patient advocacy groups
Partnering with patient groups ? the strategic imperative
Effect on physicians
2: Why companies should be interested in patient groups
Patient group support
Philanthropy
Lilly Cares ? patient assistance programme
Disaster assistance and international relief
SmithKline Beecham?s Community Partnership programme
Food and medication safety programme
Partnership General principles
Communication channels available
The pharmaceutical industry and NGO partnerships ? case studies
SmithKline Beecham and the Children?s Health Fund
Zeneca and WellSpring
Searle and Arthrocare?
Searle and Arthritis Care
Roxane Laboratories
Schering Health Care UK
Benefits for the pharmaceutical company
Lobbying
Access to patients
Clinical trials
New drug approval
Access to information
Outcomes/patient data
POM to P (prescription-only to OTC) switches
Access to funds
Patient education
Patient information
Compliance and concordance
Market research
Marketing/public relations/credibility
3: Why patient groups should be interested in drug companies
Types of partnership
Access to funding ? sponsorship
Closer working ties
Collaborative partnerships
Access to skills and competencies
Marketing
Public relations
Management
Political influence
Credibility and awareness
Shared agendas/common goals
The advance of DTC marketing
Research
Lobbying drug companies
Possible problems and conflicts
When goals differ
Legal and regulatory considerations
International standards for pharmaceutical promotion
World Health Organization ? ethical criteria
The IFPMA code
National standards for pharmaceutical promotion
FDA ? US
Other suggested controls
Controls on patient information on the Internet
1997 World Health Assembly resolution
World Health Organization
?Ethical? considerations
Ethics and perception
Ethical implications perceived in each area
What are the ethical obstacles to overcome?
Regulatory considerations
Practical considerations
Ethical considerations by therapy area
The incidence of the disease
The demography of disease
The ?urgency? of the disease
The dependency of the patient
Ethical considerations by geography
The US
Europe
Internet
Germany
Integrated patient management
The UK
Clause 20 Relations with the general public and with the media
General relationships
Africa
South Africa
SmithKline Beecham
Australia Glaxo Wellcome
Janssen
Eli Lilly
Canada
Glaxo Wellcome
European Union
Du Pont
Glaxo Wellcome
Hoffman-La Roche
SmithKline Beecham
Germany
Bayer
Pharmacia & Upjohn
Mexico
SmithKline Beecham
Russia
SmithKline Beecham
The UK
Sanofi-Winthrop
3M
Glaxo Wellcome
Leo Laboratories
Searle/Monsanto
Pharmacia & Upjohn
SmithKline Beecham
Wyeth-Ayerst
The US
Glaxo Wellcome
Eli Lilly
McNeil Consumer Products (Johnson & Johnson)
Sandoz
SmithKline Beecham
Solvay Pharmaceuticals
Warner Lambert
Patient groups with known partnerships
Consolidation in the industry
Disease management and patient power
Key issues for future consideration
To partner or not to partner, that is the question...
Direct-to-consumer marketing
Communicating with patients and patient groups ? a blueprint
Quality
Readability and legibility
Alternative sources and balance
Partnerships for all ? some lessons
Conclusions
Classification by specialty
Classification by geography
Table 1.1: Estimated numbers of active patient groups by country
Table 3.1: Patient group and pharmaceutical company skill sets
Table 5.1: Patient groups with known partnerships
Figure S.1: The new business model of ?social responsibility?
Figure 1.1: Sources of healthcare funding in the US 1990-98
Figure 1.2: Main roles of the patient group
Figure 1.3: The reach of ?patient power?
Figure 1.4: The Italian job ? reimbursement options in Italy
Figure 1.5: Early example of an Act Up! banner
Figure 2.1: The forces at play within the pharmaceutical industry
Figure 2.2: The characteristics of a partnership
Figure 2.3: Common objectives for pharmaceutical company partnerships
Figure 2.4: Types of pharmaceutical support
Figure 2.5: Sources of patient information
Figure 2.6: Dr Koop home page
Figure 2.7: Average number of patients needed per new drug application 1985-96
Figure 3.1: The process of partnership
Figure 3.2: Possible definitions of a partnership
Figure 3.3: Different levels of partnership between patient groups and pharmaceutical companies
Figure 3.4: Pattern of funding arrangements between drug companies and patient groups
Figure 3.5: Main goals of some patient groups
Figure 6.1: Future models of pharmaceutical companies
Figure 6.2: Future roles for pharmaceutical companies
Marketing
Public relations
Management
Political influence
Credibility and awareness
Shared agendas/common goals
The advance of DTC marketing
Research
Lobbying drug companies
Possible problems and conflicts
When goals differ
4: Restraining forces
Legal and regulatory considerations
International standards for pharmaceutical promotion
World Health Organization ? ethical criteria
The IFPMA code
National standards for pharmaceutical promotion
FDA ? US
Other suggested controls
Controls on patient information on the Internet
1997 World Health Assembly resolution
World Health Organization
?Ethical? considerations
Ethics and perception
Ethical implications perceived in each area
What are the ethical obstacles to overcome?
Regulatory considerations
Practical considerations
Ethical considerations by therapy area
The incidence of the disease
The demography of disease
The ?urgency? of the disease
The dependency of the patient
Ethical considerations by geography
The US
Europe
Internet
Germany
Integrated patient management
The UK
Clause 20 Relations with the general public and with the media
5: Global patient groups and their associations with the pharmaceutical Industry
General relationships
Africa
South Africa
SmithKline Beecham
Australia Glaxo Wellcome
Janssen
Eli Lilly
Canada
Glaxo Wellcome
European Union
Du Pont
Glaxo Wellcome
Hoffman-La Roche
SmithKline Beecham
Germany
Bayer
Pharmacia & Upjohn
Mexico
SmithKline Beecham
Russia
SmithKline Beecham
The UK
Sanofi-Winthrop
3M
Glaxo Wellcome
Leo Laboratories
Searle/Monsanto
Pharmacia & Upjohn
SmithKline Beecham
Wyeth-Ayerst
The US
Glaxo Wellcome
Eli Lilly
McNeil Consumer Products (Johnson & Johnson)
Sandoz
SmithKline Beecham
Solvay Pharmaceuticals
Warner Lambert
Patient groups with known partnerships
6: Future scenarios
Consolidation in the industry
Disease management and patient power
Key issues for future consideration
To partner or not to partner, that is the question...
Direct-to-consumer marketing
Communicating with patients and patient groups ? a blueprint
Quality
Readability and legibility
Alternative sources and balance
Partnerships for all ? some lessons
Conclusions
Appendix: Directory of known patient support groups
Classification by specialty
Classification by geography
European Union (published by EPHA)
Glossary and abbreviations
References
List of Tables
Table 1.1: Estimated numbers of active patient groups by country
Table 3.1: Patient group and pharmaceutical company skill sets
Table 5.1: Patient groups with known partnerships
List of Figures
Figure S.1: The new business model of ?social responsibility?
Figure 1.1: Sources of healthcare funding in the US 1990-98
Figure 1.2: Main roles of the patient group
Figure 1.3: The reach of ?patient power?
Figure 1.4: The Italian job ? reimbursement options in Italy
Figure 1.5: Early example of an Act Up! banner
Figure 2.1: The forces at play within the pharmaceutical industry
Figure 2.2: The characteristics of a partnership
Figure 2.3: Common objectives for pharmaceutical company partnerships
Figure 2.4: Types of pharmaceutical support
Figure 2.5: Sources of patient information
Figure 2.6: Dr Koop home page
Figure 2.7: Average number of patients needed per new drug application 1985-96
Figure 3.1: The process of partnership
Figure 3.2: Possible definitions of a partnership
Figure 3.3: Different levels of partnership between patient groups and pharmaceutical companies
Figure 3.4: Pattern of funding arrangements between drug companies and patient groups
Figure 3.5: Main goals of some patient groups
Figure 6.1: Future models of pharmaceutical companies
Figure 6.2: Future roles for pharmaceutical companies